CN118043327A - Fgfr抑制剂及其使用方法 - Google Patents

Fgfr抑制剂及其使用方法 Download PDF

Info

Publication number
CN118043327A
CN118043327A CN202280064436.XA CN202280064436A CN118043327A CN 118043327 A CN118043327 A CN 118043327A CN 202280064436 A CN202280064436 A CN 202280064436A CN 118043327 A CN118043327 A CN 118043327A
Authority
CN
China
Prior art keywords
phenyl
amino
methyl
pyrrolo
triazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280064436.XA
Other languages
English (en)
Chinese (zh)
Inventor
胡靖宇
付贤磊
刘艳超
张志雄
张卫波
胡邵京
陈新海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sikang Ruiqi Shanghai Pharmaceutical Co ltd
Original Assignee
Sikang Ruiqi Suzhou Pharmaceutical Co ltd
Sikang Ruiqi Shanghai Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sikang Ruiqi Suzhou Pharmaceutical Co ltd, Sikang Ruiqi Shanghai Pharmaceutical Co ltd filed Critical Sikang Ruiqi Suzhou Pharmaceutical Co ltd
Publication of CN118043327A publication Critical patent/CN118043327A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280064436.XA 2021-09-23 2022-09-23 Fgfr抑制剂及其使用方法 Pending CN118043327A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/119861 2021-09-23
CN2021119861 2021-09-23
CN2022096894 2022-06-02
CNPCT/CN2022/096894 2022-06-02
PCT/CN2022/121076 WO2023046117A1 (en) 2021-09-23 2022-09-23 Fgfr inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CN118043327A true CN118043327A (zh) 2024-05-14

Family

ID=85720119

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280064436.XA Pending CN118043327A (zh) 2021-09-23 2022-09-23 Fgfr抑制剂及其使用方法

Country Status (8)

Country Link
US (1) US20240383905A1 (https=)
EP (1) EP4405358A4 (https=)
JP (1) JP2024536858A (https=)
KR (1) KR20240075952A (https=)
CN (1) CN118043327A (https=)
AU (1) AU2022350571A1 (https=)
CA (1) CA3231948A1 (https=)
WO (1) WO2023046117A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402161A (zh) * 2022-07-06 2024-01-16 上海科恩泰生物医药科技有限公司 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途
CN115232147B (zh) * 2022-08-09 2023-10-13 南方科技大学 一种作为HIF-2α激动剂的杂环衍生物
CN120344533A (zh) * 2022-11-22 2025-07-18 海思科医药集团股份有限公司 一种嘧啶衍生物及其在医药上的应用
WO2024208315A1 (zh) * 2023-04-07 2024-10-10 中国医药研究开发中心有限公司 芳香杂环类化合物及其制备方法和医药用途
CN121002017A (zh) * 2023-05-04 2025-11-21 株式会社大熊制药 新颖的杂环胺衍生物以及包含其的药物组合物
CN121263414A (zh) * 2023-05-26 2026-01-02 上海艾力斯医药科技股份有限公司 杂芳环类化合物、其药物组合物及其应用
CN121693505A (zh) * 2023-11-17 2026-03-17 上海齐鲁制药研究中心有限公司 含氮杂芳基衍生物、其制备方法及其在医药上的应用
WO2025149021A1 (zh) * 2024-01-10 2025-07-17 海思科医药集团股份有限公司 一种吡啶并吡咯衍生物及其在医药上的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1259950A (zh) * 1997-03-19 2000-07-12 Basf公司 吡咯并[2,3d]嘧啶类化合物及它们作为酪氨酸激酶抑制剂的用途
WO2002050306A1 (en) * 2000-12-20 2002-06-27 Novartis Ag Processes for determining the biological activity of epidermal growth factor receptor tyrosine kinase inhibitors
WO2020231990A1 (en) * 2019-05-13 2020-11-19 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232823B2 (en) * 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2005061504A1 (en) * 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic pyridazinone cannabinoid receptor ligands and uses thereof
DE102008052943A1 (de) * 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
CN105837576B (zh) * 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
CN107417687A (zh) * 2016-05-24 2017-12-01 中国科学院上海药物研究所 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
CN108997380A (zh) * 2018-07-26 2018-12-14 长春海谱润斯科技有限公司 一种嘌呤化合物及其有机电致发光器件

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1259950A (zh) * 1997-03-19 2000-07-12 Basf公司 吡咯并[2,3d]嘧啶类化合物及它们作为酪氨酸激酶抑制剂的用途
WO2002050306A1 (en) * 2000-12-20 2002-06-27 Novartis Ag Processes for determining the biological activity of epidermal growth factor receptor tyrosine kinase inhibitors
WO2020231990A1 (en) * 2019-05-13 2020-11-19 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof

Also Published As

Publication number Publication date
JP2024536858A (ja) 2024-10-08
AU2022350571A1 (en) 2024-05-09
KR20240075952A (ko) 2024-05-30
EP4405358A1 (en) 2024-07-31
US20240383905A1 (en) 2024-11-21
WO2023046117A1 (en) 2023-03-30
CA3231948A1 (en) 2023-03-30
EP4405358A4 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
CN118043327A (zh) Fgfr抑制剂及其使用方法
KR102073797B1 (ko) 단백질 키나제 저해제로서의 아미노피리다지논 화합물
JP2021525783A (ja) Ｅｒｋ阻害剤及びその使用
KR101588583B1 (ko) 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
JP5328361B2 (ja) キナーゼインヒビターとして有用なアミノピリミジン
US9956220B2 (en) Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
CN102388055B (zh) 咪唑并[2,1-b][1,3,4]噻二唑衍生物
EA018282B1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
CN112279852A (zh) 三唑并-嘧啶化合物和其用途
WO2006025567A1 (ja) 新規置換イミダゾール誘導体
EP2935272B1 (en) Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
TW201801729A (zh) 6-5元稠合唑環衍生物及其藥物組合物，以及作為藥物的應用
WO2024137984A1 (en) Inhibitors of kif18a and uses thereof
WO2021244609A1 (zh) 具有大环结构的化合物及其用途
EP3854793A1 (en) Aromatic heterocyclic compound with kinase inhibitory activity
WO2023078267A1 (zh) 作为蛋白激酶调节剂的含氨基大环化合物
HK40110493A (zh) Fgfr抑制剂及其使用方法
TWI915634B (zh) Fgfr抑制劑及其使用方法
TW202400159A (zh) Fgfr抑制劑及其使用方法
HK40045058B (en) Triazolo-pyrimidine compounds and uses thereof
HK40027808B (en) Triazolo-pyrimidine compounds and uses thereof
HK40027808A (en) Triazolo-pyrimidine compounds and uses thereof
HK40026664A (en) Triazolo-pyrimidine compounds and uses thereof
HK1238630A1 (en) Pyridone derivative having tetrahydropyranyl methyl group
HK1238630B (en) Pyridone derivative having tetrahydropyranyl methyl group

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40110493

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250731

Address after: 201203 Shanghai Pudong New Area, China (Shanghai) Pilot Free Trade Zone, Room 202, Building 1, Cailun Zhilu No. 8

Applicant after: Sikang Ruiqi (Shanghai) Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: 201203 Shanghai Pudong New Area Cailun Road 85 Dong 79 Hao

Applicant before: Sikang Ruiqi (Shanghai) Pharmaceutical Co.,Ltd.

Country or region before: China

Applicant before: Sikang Ruiqi (Suzhou) Pharmaceutical Co.,Ltd.